In October 2015, letters were sent to healthcare professionals to provide safety information for the anticancer medicines crizotinib and vemurafenib
A letter regarding crizotinib has been sent to inform about the risk of cardiac failure.
A letter regarding vemurafenib has been sent to inform about the risk of potentiation of radiation toxicity.
Article citation: Drug Safety Update Vol 9 issue 4, November 2015: 3.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.